_________
false
פלוריסטם תרפיוטיקס אינק
2
381
PLURISTEM THERAPEUTICS INC
Corporation no:
C12337-2001
8544
Israel Securities Authority
Tel Aviv Stock Exchange
C003
(
Public
)
Reported via MAGNA:
29/04/2019
www.isa.gov.il
www.tase.co.il
Reference:
2019-02-037197
Time of broadcast:
13:55
13:49:46
Other Report or Announcement
Regulation 5 of the Securities Regulations, (Periodic and Immediate Reports of Foreign Corporation) 5761-2000
Please note that in the case of delayed publication of report, no changes will be allowed after the form is submitted.
Delay the publication of a report
_________
_________
1. The delay of the report can be done up to 72 hours maximum from the date of filling out the form.
2. Attention that in accordance with the provisions of the law, the reporting date must be simultaneous with the report in the foreign exchange.
The corporation is a foreign private issuer as defined by U.S. Securities Laws.
Attached hereto is a report on
Pluristem Completes Interim Enrollment in Pivotal CLI Study, Targeting Potential Conditional Marketing Approval in Europe
Pluristem_CLI_Interim_Data_recruitment_final_isa.pdf
References of previous documents relating to this matter(the reference does not constitute incorporation by reference):
Stock Exchange/Market:
NASDAQ CM
Date of revision of form structure:
19/02/2019
Address:
Matam Park
5
,
Haifa
31905
ISRAEL
,
Tel:
074-7107171
,
Fax:
074-7107172
E-mail address:
Info@Pluristem.Com
Company site:
www.pluristem.com
Previous names of reporting entity:
Name of the Signatory:
Aberman Zalman
Position of Signatory in the reporting corporation:
Chairman Of The Board & CEO
Name of Employer Company:
Address:
Matam Park
20
,
Haifa
31905
Telephone:
074-7107171
Facsimile:
074-7107172
E-mail:
zami@pluristem.com
2